RBD 4059
Alternative Names: RBD-4059Latest Information Update: 09 Oct 2023
At a glance
- Originator Suzhou Ribo Life Science
- Class Amino sugars; Antithrombotics; Drug conjugates; Small interfering RNA
- Mechanism of Action Factor XI expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Thromboembolism
Most Recent Events
- 25 Aug 2023 Pharmacodynamics and adverse events data from a preclinical trial in thromboembolism presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology (ESC-Card-2023)
- 21 Mar 2023 Phase-I clinical trials in Thromboembolism (In volunteers) in China (SC) (NCT05653037)
- 22 Dec 2022 Suzhou Ribo Life Science plans a phase I trial in Thromboembolism (In volunteers) in February 2023 (SC) (NCT05653037)